PRA International Expands Its Reach

PRA International has expanded its reach into new markets, including Asia and Latin America. This strategic move has enabled the company to tap into emerging markets and provide services to a wider range of clients.

With a presence in over 50 countries, PRA International has established itself as a global leader in the industry.

The company's expertise in clinical research and development has made it a go-to partner for pharmaceutical and biotechnology companies.

PRA International has established a presence in New Zealand, with a legal entity and staff hired to complement its Asia-Pacific operations and partnerships.

PRA's local staff will monitor New Zealand study sites, enhancing its position as a CRO gateway to the world's most rapidly expanding clinical research environment.

New Zealand is a key research location for studies in skin cancer, multiple sclerosis, asthma, and several other conditions.

The country's similar healthcare and clinical research environment to Australia makes it an ideal location for collaboration, with companies often conducting clinical trials simultaneously across both countries.

PRA International, Inc. has expanded its Scandinavian operations with the opening of a new office in Lund, Sweden. This move supports the company's continued growth in the area.

The Lund office is located in the thriving region of Oresund, a hub for life science businesses. This region is centrally situated in the Medicon Valley, one of Europe's primary centers for biotech and pharmaceutical activity.

PRA began operating in Sweden in 2005 and demand for services in the region has steadily increased. Over just the past three years, PRA's Swedish staff has increased over 350%.

The new office provides a base of operations for area staff, including clinical research associates, team leaders, country start-up specialists, and other roles needed to conduct full-service Phase II - IV clinical trials.

PRA International has expanded its operations into New Zealand, establishing a legal entity and hiring staff to complement its Asia-Pacific network and partnerships.

PRA can now monitor New Zealand study sites with in-country staff, which is a big advantage for conducting clinical trials.

New Zealand is a key research location for studies in skin cancer, multiple sclerosis, asthma, and several other conditions.

PRA's New Zealand staff will work closely with employees in the PRA Sydney, Australia office, creating an ideal situation for collaboration.

The countries share similar healthcare and clinical research environments, making it easier for companies to conduct clinical trials simultaneously across Australia and New Zealand.

New Zealand offers several advantages for PRA's expansion, including its strategic location and shared healthcare environment with Australia.

Edward Ian, PRA's Senior Director of Operations for Asia-Pacific, is pleased with the expansion to New Zealand, calling it an ideal complement to their operations in Australia.

The PRA consults on updates to its approach to international banks, publishing a consultation paper, CP11/24, on July 30, 2024.

The PRA's proposed updates include introducing additional indicative criteria for determining whether an international bank should operate in the UK as a branch or subsidiary. The PRA also proposes clarifications on booking arrangements and amendments to the branch return to improve liquidity data collection.

The deadline for responses to CP11/24 is October 30, 2024, and the PRA plans to implement the changes to SS5/21 in Q2 2025, with changes to branch reporting material implemented on December 31, 2025.

The Prudential Regulation Authority (PRA) is consulting on updates to its approach to international banks.

The PRA published a consultation paper, CP11/24, on July 30, 2024, proposing targeted updates to its approach to supervising international banks with activities in the UK.

These updates aim to reflect developments since the original framework was published and provide clarification on certain aspects of the PRA's approach.

The proposed changes include introducing additional indicative criteria for determining whether an international bank should operate in the UK as a branch or a subsidiary.

The PRA also proposes clarifying expectations around firms' booking arrangements and extending these to a subset of UK banks.

The PRA is reviewing the deposit protection limit, which will affect deposits in branches that count towards the existing indicative thresholds in SS5/21.

The deadline for responses to CP11/24 is October 30, 2024.

The PRA plans to implement the changes to SS5/21 in Q2 2025, with changes to branch reporting material implemented on December 31, 2025.

Here are the key changes proposed in CP11/24:

PRA Health Sciences wordt betaald door zijn klanten voor klinisch onderzoek op mensen, dat in drie fasen plaatsvindt: fase 1, fase 2 en fase 3.

Fase 1 vindt plaats bij gezonde vrijwilligers in speciaal hiertoe opgezette klinieken. Fase 2 vindt plaats bij kleine groepen patiënten in beperkt aantal ziekenhuizen en op vrijwillige basis. Fase 3 vindt plaats bij grote groepen patiënten in meerdere ziekenhuizen in meerdere landen, waarbij deelname ook vrijwillig is.

PRA Netherlands richt zich voornamelijk op fase 1 en in mindere mate op fase 2.

Voorafgaand aan klinisch humaan onderzoek vindt pre-klinisch onderzoek plaats, waarbij geneesmiddelen worden getest op dieren.

De minimale leeftijd voor deelnemers aan klinisch onderzoek is 18 jaar.

De deelnemers ontvangen een financiële vergoeding voor ongemak en geïnvesteerde tijd.

The Relatórios da Portugal service provides access to company reports for 30 days online, with the option to download in PDF and Excel formats.

You can access various reports, including events, brands, and financial information. The reports cover structural data, financial health, and sales volume.

The financial information includes a corporate report, financial summary, and detailed financial statements like the balance sheet and income statement.

You can also compare up to 6 companies, viewing their evolution over the past 3 years. This includes previous reports, balance sheet information, and ratios.

The comparison feature includes around 50 ratios, covering various aspects like market share, revenue, expenses, and employee numbers.